ORMP News and Press, Oramed Pharmaceuticals Inc. From 05/03/23

2023-05-03 02:30:44 ET Conservative political commentator and entrepreneur, Ben Shapiro, has taken a $4.7M stake in struggling Israeli pharma company Oramed Pharmaceuticals ( NASDAQ: ORMP ). The investment will see him join its board of directors and makes him the biggest shareh...

Oramed Pharmaceuticals Issues Shareholder Update PR Newswire NEW YORK , Feb. 9, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), announced today that it continues to conduct a comprehensive analysis of the data ...

Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...

Oramed Pharmaceuticals ( NASDAQ: ORMP ) stock fell ~10% on Tuesday after H.C. Wainwright downgraded the shares to Neutral from Buy without a price target after oral insulin therapy ORMD-0801 failed a phase 3 trial last week. Following the results, the company had said that it...

Summary On Wednesday Jan. 11, after the market had closed, Oramed announced the topline results from their phase 3 trial in Type 2 Diabetes (T2D). The trial did not meet either the primary or secondary efficacy endpoints, and there were no serious drug-related adverse events. The co...

Shares of Oramed Pharmaceuticals (NASDAQ: ORMP) are plunging today, down by 76.7% as of 11:23 a.m. ET. The steep decline came after the company announced top-line results from its late-stage clinical study evaluating experimental oral insulin ORMD-0801 in treating type 2 diabetes. Ora...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock American Virtual Cloud Technologies (NASDAQ: AVCT ) stock is taking a beating on Thursday as the company files for bankruptcy. According to a filing with the U.S. Securities and Exchange Com...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Minerva Studio / Shutterstock.com Oramed (NASDAQ: ORMP ) stock is falling hard on Thursday after releasing data from a Phase 3 clinical trial. This clinical trial saw Oramed testing the efficiency of ORMD-...

Oramed Pharmaceuticals' ( NASDAQ: ORMP ) drug ORMD-0801 did not meet the main goal of improving blood sugar levels, compared to placebo, in patients with Type 2 Diabetes (T2D) in a phase 3 trial. Oramed noted that it expects to discontinue its oral insulin clinical activities...

Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes PR Newswire NEW YORK , Jan. 11, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the dev...